ACORN Data Warehouse Contains Nearly 50 Million Data Observations
Oncology-focused CRO and research network announces its Oncology Data Warehouse includes information from over 110,000 oncology patients.
ACORN Continues Success in Oncology Data Warehousing With Accumulation of Nearly 50 Million Data Observations
MEMPHIS, Tenn., June 16 /PRNewswire/ -- Accelerated Community Oncology Research Network(TM), an oncology-focused CRO and research network, announced today that its Oncology Data Warehouse has accumulated nearly 50 million data observations from over 110,000 oncology patients contained in its data warehouse. Integrating patient-reported outcomes (PROs), electronic medical records (EMR), claims data, and laboratory information systems, garnered from community oncology practices nationwide where 85% of cancer care is provided, the warehouse contains demographically diverse data, offering reliable information on treatments and outcomes to payers, financial institutions, pharmaceutical / biotech companies, and community oncology practices.
"Our data warehouse is now mature enough to support longitudinal or cross-sectional analyses comparing practice patterns, toxicity, and outcomes in large groups of patients undergoing treatment for a broad range of tumor types," according to Ed Stepanski, Ph.D., Chief Operating Officer. "Additionally, several years of archived PACE System PROs provide a critical component to our Oncology Data Warehouse, allowing us to systematically analyze patients' symptom burden and quality of life, making our warehouse unique among all oncology data repositories."
Analytic data from this large-scale oncology data repository has been presented at many major oncology-related conferences and published in peer-
reviewed medical journals worldwide. Furthering the field of oncology health informatics, ACORN's data warehouse has been used in numerous projects that address quality of care, patients' quality of life, overall health outcomes and the cost of care.
"Determining the most effective and least toxic treatment regimens in actual clinical practice, as opposed to a clinical trial, is a valuable end result from the data warehouse," observes Steve Coplon, CEO. "ACORN will soon double the number of unique patients in the warehouse. The warehouse runs as close to real time as is needed for projects we conduct."
ACORN will exhibit at the annual Drug Information Association meeting in Boston, June 22-25, 2008. Senior level ACORN executives will be present to discuss ACORN's Oncology Data Warehouse as well as its CRO services, Guardian EDC, and network of community oncology practices. For additional information visit www.ACORNresearch.net or contact Liz Conway, Director of Marketing and Corporate Services, 901-259-0878.
Accelerated Community Oncology Research Network, Inc. (ACORN)
ACORN focuses on oncology exclusively. ACORN offers centralized clinical trial services, scientific analysis, and is a full-service Clinical Research Organization (CRO), providing contract and budgeting services; fostering accrual of subjects at the site level; collecting data and monitoring its accuracy; and working seamlessly with both trial sponsors and participating practices.
Contact Information:
Liz Conway
(901) 435-5570
lconway@sosacorn.com
www.ACORNresearch.net
Deborah D. Coble
901-683-0055x1312
dcoble@sosacorn.com
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
